Analysis of U.S. Patent 8,541,463: Scope, Claims, and Patent Landscape

U.S. Patent 8,541,463, titled "Solid Forms of Ibrutinib," was granted on September 23, 2013, to Pharmacyclics LLC. The patent covers specific crystalline forms of ibrutinib, the active pharmaceutical ingredient (API) in the cancer therapy Imbruvica. This analysis details the patent's scope, its key claims, and the broader patent landscape surrounding ibrutinib, providing insights for strategic R&D and investment.

What is the Primary Subject Matter of U.S. Patent 8,541,463?

U.S. Patent 8,541,463 primarily concerns novel solid forms of ibrutinib. Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a critical enzyme in B-cell signaling pathways implicated in various B-cell malignancies. The patent claims specific crystalline polymorphs of ibrutinib, identified as Form I and Form II, along with methods of preparing and using these forms. These crystalline forms possess distinct physical and chemical properties that are critical for drug formulation, stability, and bioavailability.

The patent describes the characterization of these forms using techniques such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). The identified polymorphs are claimed based on their unique XRPD patterns, which serve as definitive identifiers of their crystalline structure.

What are the Key Claims of U.S. Patent 8,541,463?

The claims of U.S. Patent 8,541,463 define the legal boundaries of the patented invention. The core claims focus on specific solid forms of ibrutinib and their preparation.

Claim 1: This independent claim defines a specific crystalline form of ibrutinib, referred to as "Form I." This form is characterized by specific peaks in its X-ray powder diffraction pattern, including peaks at approximately 5.7, 12.2, 16.0, 18.3, and 20.6 ± 0.2 degrees 2-theta. The claim also specifies the absence of certain other peaks, further defining the crystalline structure.
Claim 2: This claim depends on Claim 1 and further defines Form I by additional characteristic peaks in its XRPD pattern, such as 22.5, 23.4, and 25.2 ± 0.2 degrees 2-theta.
Claim 3: This claim defines another specific crystalline form of ibrutinib, "Form II." This form is characterized by a different set of XRPD peaks, including approximately 5.0, 11.0, 17.3, 19.1, and 22.4 ± 0.2 degrees 2-theta.
Claim 4: This claim depends on Claim 3 and further defines Form II by additional characteristic peaks in its XRPD pattern, such as 24.6, 26.5, and 28.7 ± 0.2 degrees 2-theta.
Claim 5: This claim is directed to a process for preparing Form I of ibrutinib. It describes a specific crystallization method involving dissolving ibrutinib in a solvent system and inducing crystallization under controlled conditions.
Claim 6: This claim is directed to a process for preparing Form II of ibrutinib, employing a similar crystallization methodology but yielding the distinct Form II polymorph.
Claim 7: This claim covers a pharmaceutical composition comprising Form I of ibrutinib and a pharmaceutically acceptable carrier.
Claim 8: This claim covers a pharmaceutical composition comprising Form II of ibrutinib and a pharmaceutically acceptable carrier.
Claim 9: This claim broadly covers a method of treating a B-cell malignancy in a subject, comprising administering an effective amount of ibrutinib, where the ibrutinib is in Form I.
Claim 10: This claim covers a method of treating a B-cell malignancy in a subject, comprising administering an effective amount of ibrutinib, where the ibrutinib is in Form II.

The patent’s claims are narrowly focused on these specific crystalline forms and their preparation and therapeutic use. This specificity is common for patents claiming polymorphs, as different crystalline forms of the same API can exhibit significant differences in solubility, stability, and manufacturing properties.

What is the Regulatory Status and Exclusivity for Ibrutinib?

Ibrutinib, marketed as Imbruvica, received its first U.S. Food and Drug Administration (FDA) approval on November 13, 2013, for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. This approval occurred shortly after the grant of U.S. Patent 8,541,463.

The regulatory pathway for Imbruvica has since expanded to include approvals for a range of B-cell malignancies, including:

Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia (WM)
Chronic graft versus host disease (cGVHD) after failure of at least one prior systemic therapy
Marginal zone lymphoma (MZL) requiring systemic therapy and who have received at least one prior therapy

The patent protection for ibrutinib has been complex, involving multiple patents covering the compound itself, its synthesis, formulations, and specific crystalline forms. U.S. Patent 8,541,463 is one of several key patents that contributed to the market exclusivity of Imbruvica.

The primary compound patent for ibrutinib, U.S. Patent 7,514,444, was filed on March 23, 2007, and granted on April 7, 2009. This patent, along with others, established a robust intellectual property portfolio for the drug.

The listed patent term for U.S. Patent 8,541,463 is 20 years from the filing date, which was September 1, 2011. Therefore, its expiration date is September 1, 2031. However, patent term adjustments (PTAs) and potential extensions, such as those granted under the Hatch-Waxman Act for regulatory delays, can alter the effective expiration date. For pharmaceuticals like ibrutinib, patent term extensions (PTEs) are crucial. Imbruvica has received PTEs for several of its patents due to FDA review periods.

The exclusivity period granted by U.S. Patent 8,541,463, combined with other patents covering ibrutinib, has been instrumental in the commercial success of Imbruvica. Generic manufacturers typically challenge these patents to gain market entry.

What is the Patent Landscape for Ibrutinib and Related Solid Forms?

The patent landscape for ibrutinib is characterized by a layered strategy involving multiple patent families covering various aspects of the drug's development and commercialization. U.S. Patent 8,541,463 is a significant component of this strategy, specifically addressing the solid-state properties of the API.

Key aspects of the ibrutinib patent landscape include:

Core Compound Patents: These patents cover the ibrutinib molecule itself. U.S. Patent 7,514,444 is a foundational patent in this category. The claims of these patents are typically broad, covering the compound regardless of its specific form or formulation.
Polymorph Patents: U.S. Patent 8,541,463 falls into this category. Patents claiming specific crystalline forms are critical for extending market exclusivity. Different polymorphs can offer advantages in terms of stability, dissolution rates, manufacturability, and patentability, thereby creating new barriers to generic entry even after the core compound patent expires. The claims for polymorphs are highly specific, defining the solid form by its unique physical characteristics (e.g., XRPD data).
Process Patents: Patents claiming specific methods for synthesizing ibrutinib or preparing its various forms are also prevalent. These can provide further layers of protection, making it difficult for competitors to produce the drug even if the compound patent has expired or been invalidated.
Formulation Patents: Patents covering specific pharmaceutical compositions, dosages, or delivery systems of ibrutinib contribute to the overall IP strategy. These might claim particular excipients, stabilizers, or methods of administering the drug.
Method of Use Patents: These patents claim novel therapeutic uses for ibrutinib, such as its application in treating specific indications or patient populations. As new indications are discovered and approved, new method of use patents can be filed and granted, extending exclusivity for those specific applications.

Competitive Patent Activity:

Generic manufacturers actively scrutinize the patent portfolio of successful drugs like Imbruvica, seeking to invalidate existing patents or design around them. Patent litigation is common in this space. Challenges often target the novelty, obviousness, or enablement of the patented claims.

Invalidation Challenges: Generic companies may file Paragraph IV certifications under the Hatch-Waxman Act, challenging the validity or enforceability of patents listed in the FDA's Orange Book. This can trigger patent litigation.
Design-Around Strategies: Competitors may attempt to develop alternative synthetic routes, different polymorphs, or novel formulations that do not infringe upon existing patents. However, the strength and breadth of patents like U.S. Patent 8,541,463, covering specific solid forms, can make such strategies challenging.

Key Players and Timeline:

Pharmacyclics LLC (now a subsidiary of AbbVie) is the primary patent holder for ibrutinib and its associated technologies. The patent landscape has evolved over time with ongoing filings and grants.

Initial Filings: The foundational patent, U.S. Patent 7,514,444, was filed in 2007.
Polymorph Filings: U.S. Patent 8,541,463 was filed in 2011, indicating a strategy to secure protection for specific solid forms after the initial compound patent.
Market Entry: Imbruvica was approved in late 2013, benefiting from the granted patents.
Ongoing Litigation and Challenges: As patents approach expiration or as generic interest grows, patent litigation and challenges become more prominent.

The existence of patents like U.S. Patent 8,541,463, which claim specific, advantageous crystalline forms, is a crucial element in maintaining market exclusivity beyond the life of the original compound patent. These patents require a deep understanding of solid-state chemistry and intellectual property law to navigate.

What are the Implications for R&D and Investment?

The analysis of U.S. Patent 8,541,463 and its surrounding patent landscape has direct implications for R&D investment and strategic decision-making.

For Pharmaceutical Companies and R&D:

Pipeline Development: Understanding the patent expiration dates and remaining exclusivity for blockbuster drugs like Imbruvica is critical for identifying potential market entry opportunities for generics or biosimilars. However, the presence of polymorph patents like 8,541,463 requires careful consideration. Developing a generic version would necessitate either obtaining a license, challenging the patent's validity, or developing a non-infringing process that yields a different solid form or a non-crystalline API.
IP Strategy for New APIs: The layered patent strategy employed for ibrutinib, including securing patents on specific crystalline forms, serves as a model. Companies developing new APIs should consider filing for patents on advantageous polymorphs early in the development process. This requires early characterization of solid forms and assessment of their properties.
Formulation Development: The patent claims for specific solid forms (Form I and Form II) highlight the importance of solid-state properties in drug development. R&D teams must conduct thorough solid-state characterization to identify stable, manufacturable crystalline forms and to ensure freedom to operate.
Litigation Risk Assessment: Companies considering generic entry must perform detailed patent landscaping and freedom-to-operate analyses. Litigation over polymorph patents can be complex and costly, requiring expertise in patent law and analytical chemistry.

For Investors:

Market Exclusivity Analysis: Investors need to assess the remaining market exclusivity for drugs protected by multiple patents, including polymorph patents. The expiration date of U.S. Patent 8,541,463 (September 1, 2031, subject to PTA/PTE) indicates a substantial period of continued exclusivity for the specific forms it covers.
Generic Entry Timing: The timing of generic entry is heavily influenced by patent expiry and the success of any patent challenges. Investors should monitor patent litigation and regulatory filings related to Imbruvica.
Valuation of IP Portfolios: For companies developing similar therapeutics, the strength and breadth of their IP portfolio, including patents on specific solid forms, will significantly impact their valuation and potential for market success.
R&D Investment Decisions: Investors may favor companies with robust IP strategies that include protecting novel crystalline forms, as this can provide a competitive advantage and extend product life cycles. Conversely, investing in companies solely reliant on expiring compound patents may carry higher risk.

The patent landscape for ibrutinib demonstrates a strategic approach to maximizing market exclusivity. U.S. Patent 8,541,463 plays a vital role in this strategy by protecting specific crystalline forms that are critical for the drug's performance and manufacturing. Understanding these patents is essential for any entity operating within the oncology drug development and investment sectors.

Key Takeaways

U.S. Patent 8,541,463 protects specific crystalline forms (Form I and Form II) of ibrutinib, the API in Imbruvica.
The patent claims are characterized by detailed XRPD data, defining the unique crystalline structures.
The patent's expiration date is September 1, 2031, subject to potential patent term adjustments or extensions.
Ibrutinib has a robust patent portfolio, including compound patents and patents on specific solid forms, which has contributed to its market exclusivity.
The patent landscape is dynamic, with potential for generic challenges and litigation.
For R&D, protecting specific crystalline forms is a critical IP strategy. For investors, assessing remaining exclusivity and patent litigation risk is paramount.

Frequently Asked Questions

What is the primary therapeutic indication for ibrutinib?

Ibrutinib is primarily used to treat various B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.

How does U.S. Patent 8,541,463 differ from a patent on the ibrutinib compound itself?

A patent on the ibrutinib compound (e.g., U.S. Patent 7,514,444) claims the molecule regardless of its physical form. U.S. Patent 8,541,463 specifically claims distinct crystalline forms (polymorphs) of ibrutinib, which have unique physical properties and manufacturing characteristics.

What is an X-ray powder diffraction (XRPD) pattern in the context of this patent?

An XRPD pattern is a unique "fingerprint" of a crystalline solid. It is generated by passing X-rays through a sample of the crystalline material, causing diffraction at specific angles that are characteristic of the crystal's internal atomic arrangement. The patent uses specific XRPD peaks to define and differentiate the claimed crystalline forms of ibrutinib.

Can a generic manufacturer produce ibrutinib if U.S. Patent 8,541,463 is still in force?

A generic manufacturer can only produce and market ibrutinib if they do not infringe any valid and unexpired patents. If U.S. Patent 8,541,463 is still in force and covers the specific crystalline form the generic intends to use, they would need to challenge the patent's validity, obtain a license, or develop a non-infringing solid form or manufacturing process.

What is the significance of pharmaceutical companies patenting specific crystalline forms of a drug?

Patenting specific crystalline forms is a strategy to extend market exclusivity beyond the life of the original compound patent. Different polymorphs can offer advantages in terms of stability, solubility, bioavailability, and manufacturability, making them valuable targets for intellectual property protection. This can prevent generic competitors from entering the market with a version of the drug formulated with a different, potentially more advantageous, crystalline form.

Citations

[1] Pharmacyclics LLC. (2013). Solid Forms of Ibrutinib (U.S. Patent No. 8,541,463). Washington, DC: U.S. Patent and Trademark Office. [2] Pharmacyclics LLC. (2009). Substituted pyrazolopyrimidines (U.S. Patent No. 7,514,444). Washington, DC: U.S. Patent and Trademark Office. [3] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from FDA Drug Database (Specific Imbruvica approval dates and indications can be found here).

Title:	Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract:	Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s):	Muller; Christopher A. (Foothill Ranch, CA), Cheetham; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA), Power; David F. (Trabuco Canyon, CA)
Assignee:	Allergan Sales, LLC (Irvine, CA)
Application Number:	13/740,426
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,541,463
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 8,541,463: Scope, Claims, and Patent Landscape U.S. Patent 8,541,463, titled "Solid Forms of Ibrutinib," was granted on September 23, 2013, to Pharmacyclics LLC. The patent covers specific crystalline forms of ibrutinib, the active pharmaceutical ingredient (API) in the cancer therapy Imbruvica. This analysis details the patent's scope, its key claims, and the broader patent landscape surrounding ibrutinib, providing insights for strategic R&D and investment. What is the Primary Subject Matter of U.S. Patent 8,541,463? U.S. Patent 8,541,463 primarily concerns novel solid forms of ibrutinib. Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a critical enzyme in B-cell signaling pathways implicated in various B-cell malignancies. The patent claims specific crystalline polymorphs of ibrutinib, identified as Form I and Form II, along with methods of preparing and using these forms. These crystalline forms possess distinct physical and chemical properties that are critical for drug formulation, stability, and bioavailability. The patent describes the characterization of these forms using techniques such as X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). The identified polymorphs are claimed based on their unique XRPD patterns, which serve as definitive identifiers of their crystalline structure. What are the Key Claims of U.S. Patent 8,541,463? The claims of U.S. Patent 8,541,463 define the legal boundaries of the patented invention. The core claims focus on specific solid forms of ibrutinib and their preparation. Claim 1: This independent claim defines a specific crystalline form of ibrutinib, referred to as "Form I." This form is characterized by specific peaks in its X-ray powder diffraction pattern, including peaks at approximately 5.7, 12.2, 16.0, 18.3, and 20.6 ± 0.2 degrees 2-theta. The claim also specifies the absence of certain other peaks, further defining the crystalline structure. Claim 2: This claim depends on Claim 1 and further defines Form I by additional characteristic peaks in its XRPD pattern, such as 22.5, 23.4, and 25.2 ± 0.2 degrees 2-theta. Claim 3: This claim defines another specific crystalline form of ibrutinib, "Form II." This form is characterized by a different set of XRPD peaks, including approximately 5.0, 11.0, 17.3, 19.1, and 22.4 ± 0.2 degrees 2-theta. Claim 4: This claim depends on Claim 3 and further defines Form II by additional characteristic peaks in its XRPD pattern, such as 24.6, 26.5, and 28.7 ± 0.2 degrees 2-theta. Claim 5: This claim is directed to a process for preparing Form I of ibrutinib. It describes a specific crystallization method involving dissolving ibrutinib in a solvent system and inducing crystallization under controlled conditions. Claim 6: This claim is directed to a process for preparing Form II of ibrutinib, employing a similar crystallization methodology but yielding the distinct Form II polymorph. Claim 7: This claim covers a pharmaceutical composition comprising Form I of ibrutinib and a pharmaceutically acceptable carrier. Claim 8: This claim covers a pharmaceutical composition comprising Form II of ibrutinib and a pharmaceutically acceptable carrier. Claim 9: This claim broadly covers a method of treating a B-cell malignancy in a subject, comprising administering an effective amount of ibrutinib, where the ibrutinib is in Form I. Claim 10: This claim covers a method of treating a B-cell malignancy in a subject, comprising administering an effective amount of ibrutinib, where the ibrutinib is in Form II. The patent’s claims are narrowly focused on these specific crystalline forms and their preparation and therapeutic use. This specificity is common for patents claiming polymorphs, as different crystalline forms of the same API can exhibit significant differences in solubility, stability, and manufacturing properties. What is the Regulatory Status and Exclusivity for Ibrutinib? Ibrutinib, marketed as Imbruvica, received its first U.S. Food and Drug Administration (FDA) approval on November 13, 2013, for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. This approval occurred shortly after the grant of U.S. Patent 8,541,463. The regulatory pathway for Imbruvica has since expanded to include approvals for a range of B-cell malignancies, including: Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) Waldenström's macroglobulinemia (WM) Chronic graft versus host disease (cGVHD) after failure of at least one prior systemic therapy Marginal zone lymphoma (MZL) requiring systemic therapy and who have received at least one prior therapy The patent protection for ibrutinib has been complex, involving multiple patents covering the compound itself, its synthesis, formulations, and specific crystalline forms. U.S. Patent 8,541,463 is one of several key patents that contributed to the market exclusivity of Imbruvica. The primary compound patent for ibrutinib, U.S. Patent 7,514,444, was filed on March 23, 2007, and granted on April 7, 2009. This patent, along with others, established a robust intellectual property portfolio for the drug. The listed patent term for U.S. Patent 8,541,463 is 20 years from the filing date, which was September 1, 2011. Therefore, its expiration date is September 1, 2031. However, patent term adjustments (PTAs) and potential extensions, such as those granted under the Hatch-Waxman Act for regulatory delays, can alter the effective expiration date. For pharmaceuticals like ibrutinib, patent term extensions (PTEs) are crucial. Imbruvica has received PTEs for several of its patents due to FDA review periods. The exclusivity period granted by U.S. Patent 8,541,463, combined with other patents covering ibrutinib, has been instrumental in the commercial success of Imbruvica. Generic manufacturers typically challenge these patents to gain market entry. What is the Patent Landscape for Ibrutinib and Related Solid Forms? The patent landscape for ibrutinib is characterized by a layered strategy involving multiple patent families covering various aspects of the drug's development and commercialization. U.S. Patent 8,541,463 is a significant component of this strategy, specifically addressing the solid-state properties of the API. Key aspects of the ibrutinib patent landscape include: Core Compound Patents: These patents cover the ibrutinib molecule itself. U.S. Patent 7,514,444 is a foundational patent in this category. The claims of these patents are typically broad, covering the compound regardless of its specific form or formulation. Polymorph Patents: U.S. Patent 8,541,463 falls into this category. Patents claiming specific crystalline forms are critical for extending market exclusivity. Different polymorphs can offer advantages in terms of stability, dissolution rates, manufacturability, and patentability, thereby creating new barriers to generic entry even after the core compound patent expires. The claims for polymorphs are highly specific, defining the solid form by its unique physical characteristics (e.g., XRPD data). Process Patents: Patents claiming specific methods for synthesizing ibrutinib or preparing its various forms are also prevalent. These can provide further layers of protection, making it difficult for competitors to produce the drug even if the compound patent has expired or been invalidated. Formulation Patents: Patents covering specific pharmaceutical compositions, dosages, or delivery systems of ibrutinib contribute to the overall IP strategy. These might claim particular excipients, stabilizers, or methods of administering the drug. Method of Use Patents: These patents claim novel therapeutic uses for ibrutinib, such as its application in treating specific indications or patient populations. As new indications are discovered and approved, new method of use patents can be filed and granted, extending exclusivity for those specific applications. Competitive Patent Activity: Generic manufacturers actively scrutinize the patent portfolio of successful drugs like Imbruvica, seeking to invalidate existing patents or design around them. Patent litigation is common in this space. Challenges often target the novelty, obviousness, or enablement of the patented claims. Invalidation Challenges: Generic companies may file Paragraph IV certifications under the Hatch-Waxman Act, challenging the validity or enforceability of patents listed in the FDA's Orange Book. This can trigger patent litigation. Design-Around Strategies: Competitors may attempt to develop alternative synthetic routes, different polymorphs, or novel formulations that do not infringe upon existing patents. However, the strength and breadth of patents like U.S. Patent 8,541,463, covering specific solid forms, can make such strategies challenging. Key Players and Timeline: Pharmacyclics LLC (now a subsidiary of AbbVie) is the primary patent holder for ibrutinib and its associated technologies. The patent landscape has evolved over time with ongoing filings and grants. Initial Filings: The foundational patent, U.S. Patent 7,514,444, was filed in 2007. Polymorph Filings: U.S. Patent 8,541,463 was filed in 2011, indicating a strategy to secure protection for specific solid forms after the initial compound patent. Market Entry: Imbruvica was approved in late 2013, benefiting from the granted patents. Ongoing Litigation and Challenges: As patents approach expiration or as generic interest grows, patent litigation and challenges become more prominent. The existence of patents like U.S. Patent 8,541,463, which claim specific, advantageous crystalline forms, is a crucial element in maintaining market exclusivity beyond the life of the original compound patent. These patents require a deep understanding of solid-state chemistry and intellectual property law to navigate. What are the Implications for R&D and Investment? The analysis of U.S. Patent 8,541,463 and its surrounding patent landscape has direct implications for R&D investment and strategic decision-making. For Pharmaceutical Companies and R&D: Pipeline Development: Understanding the patent expiration dates and remaining exclusivity for blockbuster drugs like Imbruvica is critical for identifying potential market entry opportunities for generics or biosimilars. However, the presence of polymorph patents like 8,541,463 requires careful consideration. Developing a generic version would necessitate either obtaining a license, challenging the patent's validity, or developing a non-infringing process that yields a different solid form or a non-crystalline API. IP Strategy for New APIs: The layered patent strategy employed for ibrutinib, including securing patents on specific crystalline forms, serves as a model. Companies developing new APIs should consider filing for patents on advantageous polymorphs early in the development process. This requires early characterization of solid forms and assessment of their properties. Formulation Development: The patent claims for specific solid forms (Form I and Form II) highlight the importance of solid-state properties in drug development. R&D teams must conduct thorough solid-state characterization to identify stable, manufacturable crystalline forms and to ensure freedom to operate. Litigation Risk Assessment: Companies considering generic entry must perform detailed patent landscaping and freedom-to-operate analyses. Litigation over polymorph patents can be complex and costly, requiring expertise in patent law and analytical chemistry. For Investors: Market Exclusivity Analysis: Investors need to assess the remaining market exclusivity for drugs protected by multiple patents, including polymorph patents. The expiration date of U.S. Patent 8,541,463 (September 1, 2031, subject to PTA/PTE) indicates a substantial period of continued exclusivity for the specific forms it covers. Generic Entry Timing: The timing of generic entry is heavily influenced by patent expiry and the success of any patent challenges. Investors should monitor patent litigation and regulatory filings related to Imbruvica. Valuation of IP Portfolios: For companies developing similar therapeutics, the strength and breadth of their IP portfolio, including patents on specific solid forms, will significantly impact their valuation and potential for market success. R&D Investment Decisions: Investors may favor companies with robust IP strategies that include protecting novel crystalline forms, as this can provide a competitive advantage and extend product life cycles. Conversely, investing in companies solely reliant on expiring compound patents may carry higher risk. The patent landscape for ibrutinib demonstrates a strategic approach to maximizing market exclusivity. U.S. Patent 8,541,463 plays a vital role in this strategy by protecting specific crystalline forms that are critical for the drug's performance and manufacturing. Understanding these patents is essential for any entity operating within the oncology drug development and investment sectors. Key Takeaways U.S. Patent 8,541,463 protects specific crystalline forms (Form I and Form II) of ibrutinib, the API in Imbruvica. The patent claims are characterized by detailed XRPD data, defining the unique crystalline structures. The patent's expiration date is September 1, 2031, subject to potential patent term adjustments or extensions. Ibrutinib has a robust patent portfolio, including compound patents and patents on specific solid forms, which has contributed to its market exclusivity. The patent landscape is dynamic, with potential for generic challenges and litigation. For R&D, protecting specific crystalline forms is a critical IP strategy. For investors, assessing remaining exclusivity and patent litigation risk is paramount. Frequently Asked Questions What is the primary therapeutic indication for ibrutinib? Ibrutinib is primarily used to treat various B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease. How does U.S. Patent 8,541,463 differ from a patent on the ibrutinib compound itself? A patent on the ibrutinib compound (e.g., U.S. Patent 7,514,444) claims the molecule regardless of its physical form. U.S. Patent 8,541,463 specifically claims distinct crystalline forms (polymorphs) of ibrutinib, which have unique physical properties and manufacturing characteristics. What is an X-ray powder diffraction (XRPD) pattern in the context of this patent? An XRPD pattern is a unique "fingerprint" of a crystalline solid. It is generated by passing X-rays through a sample of the crystalline material, causing diffraction at specific angles that are characteristic of the crystal's internal atomic arrangement. The patent uses specific XRPD peaks to define and differentiate the claimed crystalline forms of ibrutinib. Can a generic manufacturer produce ibrutinib if U.S. Patent 8,541,463 is still in force? A generic manufacturer can only produce and market ibrutinib if they do not infringe any valid and unexpired patents. If U.S. Patent 8,541,463 is still in force and covers the specific crystalline form the generic intends to use, they would need to challenge the patent's validity, obtain a license, or develop a non-infringing solid form or manufacturing process. What is the significance of pharmaceutical companies patenting specific crystalline forms of a drug? Patenting specific crystalline forms is a strategy to extend market exclusivity beyond the life of the original compound patent. Different polymorphs can offer advantages in terms of stability, solubility, bioavailability, and manufacturability, making them valuable targets for intellectual property protection. This can prevent generic competitors from entering the market with a version of the drug formulated with a different, potentially more advantageous, crystalline form. Citations [1] Pharmacyclics LLC. (2013). Solid Forms of Ibrutinib (U.S. Patent No. 8,541,463). Washington, DC: U.S. Patent and Trademark Office. [2] Pharmacyclics LLC. (2009). Substituted pyrazolopyrimidines (U.S. Patent No. 7,514,444). Washington, DC: U.S. Patent and Trademark Office. [3] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from FDA Drug Database (Specific Imbruvica approval dates and indications can be found here). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2468664	⤷ Start Trial
Canada	2967362	⤷ Start Trial
European Patent Office	3217937	⤷ Start Trial
European Patent Office	3777808	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2016077726	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,541,463

Summary for Patent: 8,541,463